Teri-Pro Study
Patient-reported outcomes in patients with relapsing forms of MS switching to teriflunomide from other disease-modifying therapies: Results from the global Phase 4 Teri-PRO study in routine clinical practice.
![](/.imaging/webp/sanofi-templates/w1080-16-9/dam/campus-sanofi-bh/campus-sanofi-bh-new/science/Images/image---2023-10-05T173109.365.png/jcr:content/image%20-%202023-10-05T173109.365.png)
Related articles
MAT-BH-2100670-V1, September 2021